We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00436384
Recruitment Status : Completed
First Posted : February 19, 2007
Last Update Posted : April 16, 2008
Information provided by:

Study Description
Brief Summary:
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. Since transplant recipients are at risk for CMV or have evidence of infection with CMV, they are given an antiviral drug (usually ganciclovir or valganciclovir). Despite this, there are a chance that CMV infection may cause problems in the future. The purpose of this study is to assess how well patients'immune systems responds to the CMV virus, so that in the future it may be possible to predict which patients are at highest risk of CMV.

Condition or disease Intervention/treatment Phase
Transplant Procedure: Monitoring-blood samples drawn for CMV testing Phase 4

Study Design

Study Type : Observational
Estimated Enrollment : 150 participants
Official Title: Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients
Study Start Date : November 2005
Primary Completion Date : March 2008
Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients who fulfill the following criteria are eligible for inclusion.

    • CMV D+/R- liver, kidney and heart recipient
    • CMV R+ liver,kidney and heart recipients who have received thymoglobulin induction therapy.
    • D+/R- and R+ lung transplant recipients.
    • Able to give written informed consent
    • Are willing and able to comply with the protocol
    • Age >=18 years

Exclusion Criteria:

  • Patient unwilling or unable to give informed consent
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00436384

Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2N2
Sponsors and Collaborators
University Health Network, Toronto
The Physicians' Services Incorporated Foundation
Principal Investigator: Atul Humar, MD University Health Network, Toronto
Principal Investigator: Deepali Kumar, MD University Health Network, Toronto
More Information

ClinicalTrials.gov Identifier: NCT00436384     History of Changes
Other Study ID Numbers: 05-0265-AE
First Posted: February 19, 2007    Key Record Dates
Last Update Posted: April 16, 2008
Last Verified: February 2007

Keywords provided by University Health Network, Toronto:
liver transplant
lung transplant
kidney transplant
heart transplant

Additional relevant MeSH terms:
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases